NanoViricides Inc  

(Public, NYSEAMERICAN:NNVC)   Watch this stock  
0.990
+0.006 (0.60%)
Nov 23 - Close
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 0.99 - 1.01
52 week 0.91 - 1.64
Open 1.01
Vol / Avg. 83,887.00/157,376.00
Mkt cap 62.71M
P/E     -
Div/yield     -
EPS -0.15
Shares 63.34M
Beta 0.25
Inst. own 6%
Feb 12, 2018
Q2 2018 NanoViricides Inc Earnings Release (Estimated) Add to calendar
Nov 20, 2017
Q1 2018 NanoViricides Inc Earnings Release
Sep 28, 2017
Q4 2017 NanoViricides Inc Earnings Release
Sep 12, 2017
NanoViricides Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.78% -32.39%
Return on average equity -41.43% -47.53%
Employees 30 -
CDP Score - -

Address

1 Controls Dr
SHELTON, CT 06484-6153
United States - Map
+1-203-9376137 (Phone)
+1-203-8595095 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

Officers and directors

Anil Diwan Ph.D. Chairman of the Board, President
Age: 57
Bio & Compensation  - Reuters
Eugene Seymour M.D. Chief Executive Officer, Director
Age: 75
Bio & Compensation  - Reuters
Meeta Vyas Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Milton Boniuk Independent Director
Age: 83
Bio & Compensation  - Reuters
Stanley Glick CPA Independent Director
Age: 79
Bio & Compensation  - Reuters
Mukund S. Kulkarni Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters